To amend the Federal Food, Drug, and Cosmetic Act to establish nonvisual accessibility standards for certain devices with digital interfaces, and for other purposes.
Summary
What This Bill Does
The bill requires findings Congress finds the following: Rapid advances in digital technology have led to increasingly complex user interfaces for everyday products, such as life-sustaining medical devices and technologies, creates nonvisual accessibility standards for certain devices Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C, and provides nonvisual accessibility standards for certain devices The nonvisual accessibility standard specified in this section is, with respect to a user interface of a device described in section 501(k), that the user. It relies on compliance mandates, product standards, appropriations, and reporting requirements. The main policy areas are Healthcare Consumers, Healthcare, Transportation, and Finance.
Who Benefits and How
Transportation operators and users affected by the bill could gain revenue opportunities, Patients and health care consumers affected by the bill could face lower compliance burdens, and Public beneficiaries or protected communities affected by the clause could face reduced risk.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Researchers and scientific institutions affected by the bill would take on compliance duties, and Patients and health care consumers affected by the bill would take on compliance duties.
Key Provisions
- Requires findings Congress finds the following: Rapid advances in digital technology have led to increasingly complex user interfaces for everyday products, such as life-sustaining medical devices and technologies.
- Creates nonvisual accessibility standards for certain devices Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
- Provides nonvisual accessibility standards for certain devices The nonvisual accessibility standard specified in this section is, with respect to a user interface of a device described in section 501(k), that the user...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires findings Congress finds the following: Rapid advances in digital technology have led to increasingly complex user interfaces for everyday products, such as life-sustaining medical devices and technologies, creates nonvisual accessibility standards for certain devices Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C, and provides nonvisual accessibility standards for certain devices The nonvisual accessibility standard specified in this section is, with respect to a user interface of a device described in section 501(k), that the user.
Key Policy Areas
Healthcare Consumers, Healthcare, Transportation, Finance
Primary Purpose
The bill requires findings Congress finds the following: Rapid advances in digital technology have led to increasingly complex user interfaces for everyday products, such as life-sustaining medical devices and technologies, creates nonvisual accessibility standards for certain devices Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C, and provides nonvisual accessibility standards for certain devices The nonvisual accessibility standard specified in this section is, with respect to a user interface of a device described in section 501(k), that the user.
Policy Domains
Whole bill
Identified Gains
- Transportation operators and users affected by the bill
- Patients and health care consumers affected by the bill
- Public beneficiaries or protected communities affected by the clause
- Financial services firms and customers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
Sponsors
Legislative Progress
IntroducedMs. Schakowsky (for herself, Mr. Trone, Mr. Veasey, Mr. Bishop …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology